232 related articles for article (PubMed ID: 20494319)
1. PML: underdiagnosed in MS patients on natalizumab.
Steiner I
Lancet Neurol; 2010 Jun; 9(6):564; author reply 564-5. PubMed ID: 20494319
[No Abstract] [Full Text] [Related]
2. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
5. A giant MS plaque mimicking PML during natalizumab treatment.
Twyman C; Berger JR
J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
[TBL] [Abstract][Full Text] [Related]
6. Use of natalizumab in multiple sclerosis: current perspectives.
Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab therapy for multiple sclerosis.
Derfuss T; Kuhle J; Lindberg R; Kappos L
Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis, natalizumab, and PML: helping patients decide.
Rudick RA
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications.
Greenlee JE
Int MS J; 2006 Nov; 13(3):100-7. PubMed ID: 17101078
[TBL] [Abstract][Full Text] [Related]
10. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
12. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
Gupta S; Weinstock-Guttman B
Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
[TBL] [Abstract][Full Text] [Related]
13. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.
Dalla Costa G; Martinelli V; Moiola L; Sangalli F; Colombo B; Finardi A; Cinque P; Kolb EM; Haghikia A; Gold R; Furlan R; Comi G
Ann Neurol; 2019 Apr; 85(4):606-610. PubMed ID: 30761586
[TBL] [Abstract][Full Text] [Related]
14. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Landy DC; Hecht EM
Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab: bench to bedside and beyond.
Rudick R; Polman C; Clifford D; Miller D; Steinman L
JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
[TBL] [Abstract][Full Text] [Related]
16. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
17. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
[TBL] [Abstract][Full Text] [Related]
18. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
19. [Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI].
Gibelin N; Daelman L; Goulipian S; Wynckel A; Chaunu MP; Tourbah A
Rev Neurol (Paris); 2014 Jan; 170(1):48-50. PubMed ID: 24139244
[No Abstract] [Full Text] [Related]
20. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
